Misplaced Pages

Geron Corporation

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
American biotechnology company
This article needs to be updated. Please help update this article to reflect recent events or newly available information. (September 2021)
Geron Corporation
Company typePublic
Traded asNasdaq: GERN
Russell 2000 Component
IndustryBiotechnology
Founded1990
HeadquartersFoster City, California, U.S.
Key peopleJohn Scarlett (President, CEO)
Olivia Bloom (CFO)
ProductsCancer drugs (currently in human trials)
RevenueIncrease USD 1.39 million (2021)
Net incomeDecrease USD-$116 million (2021)
Total assetsDecrease USD$226 million (2021)
Total equityDecrease USD$126 million (2021)
Number of employees82
Websitewww.geron.com
Footnotes / references

Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.

Company information

Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. The company was incorporated in 1990 and began doing business in 1992. John A. Scarlett was appointed CEO in 2011.

The company's Scientific and Clinical Advisory Board has included Nobel laureates James Watson, Gunter Blobel, and Carol Greider, and Leonard Hayflick, known for discovering that human cells divide for a limited number of times in vitro (called the Hayflick limit).

In 2017, Geron staff received the highest median pay in California, at $500,250.

Drug candidates

Cancer therapies

Geron Corporation has sponsored human clinical trials of several potential anti-cancer products.

  • Imetelstat (GRN163L) is a drug that targets telomerase. In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. Similarly, GRN163L inhibited the in vitro clonogenic growth of CD138neg Multiple Myeloma Cancer Stem Cells isolated from the bone marrow aspirates of patients with multiple myeloma. On November 3, 2014, the FDA removed the full clinical hold on imetelstat and declared the company's clinical development plan as acceptable. In 2014, Geron licensed imetelstat to Janssen Biotech. In 2017, imetelstat was granted fast track status by the FDA for certain patients with myelodysplastic syndrome. In 2018, Janssen Biotech returned the rights to imetelstat to Geron. Imetelstat is currently in two Phase 3 trials: NCT02598661, a study of the drug's ability to reduce the transfusion requirements of patients with myelodysplastic syndrome (MDS), and NCT04576156, an investigation of the drug's effect on the overall survival of patients with myelofibrosis.
  • A trial of GRNVAC1, a telomerase vaccine being used on patients with prostate cancer was carried out at Duke University. Geron's progress with telomerase vaccines attracted a modest monetary investment in 2005 from Merck.
  • GRN1005, an LRP-directed conjugate of paclitaxel, was in phase II clinical trials for brain cancer but discontinued based on preliminary results in 2012.

Telomerase activation

In addition to testing drug candidates that exploit cancer cell's dependence on telomerase, Geron is researching the possible applications of activating the enzyme in normal cells to delay cellular senescence. The company is in the early stages of developing a telomerase based treatment for HIV called TAT0002, which is the saponin cycloastragenol in Chinese herb Astragalus propinquus. Geron has granted a license to Telomerase Activation Sciences to sell TA-65, the telomerase activator agent also derived from astragalus. In October 2010 Intertek/AAC Labs, an ISO 17025 internationally recognized lab, found the largest component of TA-65 to be cycloastragenol.

Geron originally investigated telomerase as a means of understanding and modifying human aging. However, Geron has ceased aging research of any kind.

Stem cell therapies

On January 23, 2009, Geron received FDA approval to begin Phase I testing of GRNOPC1 in humans. GRNOPC1 is an embryonic stem cell based drug that is designed to treat specific forms of spinal cord injury through remyelination of damaged axons. This trial does not involve direct use of stem cells however, as GRNOPC1 is composed of oligodendrocyte progenitor cells derived from embryonic stem cell lines. Studies have shown significant restoration of mobility in animals with spinal injuries that received cells.

Geron also has several other embryonic stem cell treatments that are still in the preclinical phase, including GRNCM1, a treatment for heart disease, and GRNIC1, a treatment for diabetes. In tests with diabetic mice, 80% of the mice given GRNIC1 were still alive in 50 days while the entire control group, which was given no treatment, perished.

Geron sold its human stem cell research assets to Asterias in 2013.

GRNOPC1

Main article: Human embryonic stem cells clinical trials § Geron Spinal Cord Injury Trial

As of October 2010 and November 2010, One of Geron's most highly publicized trial therapy products has been GRNOPC1, a stem cell therapy designed to heal severe spinal cord injuries. The cells in the GRNOPC1 therapy have been coaxed into becoming early myelinated glial cells, a type of cell that insulates nerve cells. For every GRNOPC1 cell that is injected in the patient, they become six to ten cells in a few months. In October 2011 updated results on four patients were released. The trial was discontinued in Nov 2011.

In early 2013 BioTime, whose CEO at the time was Geron founder Michael D. West, acquired 400 patents and other intellectual property related to embryonic stem cells from Geron and later went on to restart the trial.

Patent issues

Geron Corporation initially held exclusive rights to three cell types derived from embryonic stem cells, as the result of paying for the research originally conducted by Dr. James Thomson at the University of Wisconsin–Madison. The patents on the other three cell types are owned by the Wisconsin Alumni Research Foundation (WARF). WARF and Geron did not charge academics to study human stem cells but did charge commercial users. In 2001 WARF came under public pressure to widen access to human stem-cell technology, and they launched legal action against Geron Corporation to recover some of the previously sold rights. The two sides agreed that Geron would keep the rights to only three cell types.

In October 2006, a legal challenge was mounted to overturn these patents by The Foundation for Taxpayer and Consumer Rights and the non-profit patent-watchdog Public Patent Foundation. They contended that two of the patents granted to WARF are invalid because they cover a technique published in 1992 for which a patent had already been granted to an Australian researcher. Another part of the challenge came from the molecular biologist Jeanne Loring who stated that University of Wisconsin–Madison stem cell pioneer James Thomson's techniques (currently patents held by WARF) are rendered obvious by a 1990 paper and two textbooks. The outcome of this legal challenge was particularly relevant to the Geron Corporation as it can only license patents that are upheld. The patents were ultimately upheld when the reexamination concluded in 2008.

As an interim measure, on January 23, 2007, WARF relaxed the stem cell patents, allowing industry-sponsored research at academic and non-profit institutions without a license. WARF will allow easier and simpler cost free cell transfers among researchers and would not require a license or agreement from California's taxpayer-funded stem cell research program.

Politics

As a participant in the then-controversial stem cell and cloning area, Geron Corporation was asked to testify about its technology before the U.S. Congress. In 2001, when Congress was attempting to ban all forms of cloning, then Geron CEO Thomas Okarma spoke before Congress to preserve cloning for therapeutic purposes.

See also

References

  1. "Geron 2021 10K Annual Report". U.S. Securities and Exchange Commission. Retrieved 9 May 2022.
  2. "Anti-ageing drugs are coming that could keep you healthier for longer". New Scientist. April 24, 2019.
  3. Pollack, Andrew (May 18, 2011). "A Blood Test Offers Clues to Longevity". New York Times.
  4. "SEC Schedule 13G, filed Feb. 17, 1999". Archived from the original on 2016-03-06. Retrieved 2013-08-28.
  5. "Human tests of Geron's spinal-cord medication put on hold". The Mercury News. 2009-08-18. Retrieved 2020-04-29.
  6. Binstock, Robert H. (2003-07-22). "BOOKS OF THE TIMES; Quest for Infinite Youth Raises Hopes and Cash". The New York Times. ISSN 0362-4331. Retrieved 2020-04-29.
  7. Leuty, Ron (30 September 2011). "Chip Scarlett's skills may pay off – again – at Geron". San Francisco Business Times. Retrieved 15 November 2016.
  8. Hayflick L (1965). "The limited in vitro lifetime of human diploid cell strains". Experimental Cell Research. 37 (3): 614–636. doi:10.1016/0014-4827(65)90211-9. PMID 14315085.
  9. "Geron Corporation 10K 1996".
  10. Hall, Stephen (2003). "Merchants of Immortality: Chasing the New Dream of Life Extension". Houghton Mifflin. ISBN 0547561571. Page 151.
  11. Monmaney, Terence (14 January 1998). "Scientists Give Cell Apparent Immortality". Los Angeles Times.
  12. Salisbury, Ian (May 29, 2018). "This Map Shows the Best-Paying Company In Every State". Money.com. Archived from the original on September 30, 2020.
  13. "Imetelstat Sodium". NCI Drug Dictionary. National Cancer Institute. Retrieved 15 November 2016.
  14. Brennan, Sarah K.; Wang, Qiuju; Tressler, Robert; Harley, Calvin; Go, Ning; Bassett, Ekaterina; Huff, Carol Ann; Jones, Richard J.; Matsui, William; Swarbrick, Alexander (1 September 2010). "Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms". PLOS ONE. 5 (9): e12487. Bibcode:2010PLoSO...512487B. doi:10.1371/journal.pone.0012487. PMC 2931698. PMID 20824134.
  15. Alex Planes (November 3, 2014). "Why Geron Corporation Shares Skyrocketed". The Motley Fool.
  16. Fitzhugh, Michael (17 November 2014). "'New chapter' as Geron lands potential $935M imetelstat deal with Janssen". BioWorld.
  17. "Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat". Investor Relations: Press Release. Geron. Archived from the original on September 5, 2015. Retrieved 2018-02-25.
  18. Corporation, Geron. "Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk myelodysplastic syndromes". GlobeNewswire News Room. Retrieved 2018-02-25.
  19. "Geron shares crater as Janssen bows out of imetelstat pact once worth up to $935M". FierceBiotech. Retrieved 2021-01-05.
  20. Geron Corporation (2021-01-04). "A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment". Clinical Trials.
  21. Geron Corporation (2020-12-23). "A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor". Clinical Trials.
  22. Harley, Calvin B. (March 2008). "Telomerase and cancer therapeutics". Nature Reviews Cancer. 8 (3): 167–179. doi:10.1038/nrc2275. PMID 18256617. S2CID 39599576.
  23. "Geron plans stock offering, Merck buying $18M in shares". 12 September 2005.
  24. "Geron Scraps GRN1005, Cuts Jobs". Zacks Investment Research. Retrieved 15 November 2016.
  25. Fauce, Steven Russell; Jamieson, Beth D.; Chin, Allison C.; Mitsuyasu, Ronald T.; Parish, Stan T.; Ng, Hwee L.; Ramirez Kitchen, Christina M.; Yang, Otto O.; Harley, Calvin B.; Effros, Rita B. (2008). "Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8 T Lymphocytes". The Journal of Immunology. 181 (10): 7400–7406. doi:10.4049/jimmunol.181.10.7400. PMC 2682219. PMID 18981163.
  26. Borrell, Brendan (2 August 2012). "Lawsuit challenges anti-ageing claims". Nature. 488 (7409): 18. Bibcode:2012Natur.488...18B. doi:10.1038/488018a. PMID 22859181.
  27. American Analytical Chemistry Laboratories Analysis Document #100710-236 of TA-65
  28. Ron Leuty (November 15, 2012). "Geron to sell embryonic stem cell business to BioTime". San Francisco Business Times. Retrieved 2020-12-14.
  29. "Despite Bush Veto, Stem Cell Research Abounds – Forbes.com". Forbes. Archived from the original on February 4, 2007.
  30. Keirstead HS, Nistor G, Bernal G, et al. (May 2005). "Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury". J. Neurosci. 25 (19): 4694–705. doi:10.1523/JNEUROSCI.0311-05.2005. PMC 6724772. PMID 15888645.
  31. News: Geron Presents New Data That Document Progress in Development of Therapeutic Products from Human Embryonic Stem Cells. Genetic Engineering & Biotechnology News – Biotechnology from Bench to Business
  32. "Geron Announces Record Date for Distribution of Asterias Series A Common Stock". Yahoo Finance. Retrieved 15 November 2016.
  33. CNN Rachel Meade Reports (October 13, 2010)
  34. "Geron (GERN) updates Clinical Data from GRNOPC1 Spinal Cord Injury Trial". 20 Oct 2011. Archived from the original on 2011-10-23.
  35. "Geron's Stem Cell Program Sold". The Scientist. October 2, 2013.
  36. "BioTime acquires stem cell assets from Geron, raises $10 million". San Francisco Business Times. January 7, 2013.
  37. "Funding windfall rescues abandoned stem-cell trial". Nature. June 3, 2014.
  38. Westhoff, Julia (22 January 2002). "WARF, Geron reach settlement". The Badger Herald.
  39. Regalado, Antonio; Hamilton, David P. (18 July 2006). "How a University's Patents May Limit Stem-Cell Research". Wall Street Journal.
  40. Kintisch, E. (21 July 2006). "Groups Challenge Key Stem Cell Patents". Science. 313 (5785): 281. doi:10.1126/science.313.5785.281. PMID 16857907. S2CID 167760607.
  41. Loring, Jeanne (8 November 2007). "A patent challenge for human embryonic stem cell research". Nature Reports Stem Cells. doi:10.1038/stemcells.2007.113.
  42. "Stem Cell Patents Come Under Fire". Center for Genetics and Society. Associated Press. 19 July 2006.
  43. "WARF press release". Archived from the original on 2008-09-22. Retrieved 2008-10-02.
  44. Somers, Terri (23 January 2007). "Stem cell scientists shout out hallelujah". The San Diego Union-Tribune.
  45. "Wisconsin Group Eases Stem Cell Patent Restrictions After FTCR". PUBPAT. 23 January 2007. Retrieved 5 September 2013.
  46. Herper, Matthew (April 5, 2001). "Geron's Cloning Quandary – Forbes.com". Forbes.
  47. "Online Extra: Thomas Okarma: Don't Ban Stem-Cell Research". BusinessWeek. 2 June 2003. Archived from the original on 22 May 2011.
  48. "House Hearing, 107th Congress – The Human Cloning Prohibition Act of 2001 and The Cloning Prohibition Act of 2001", U.S. Government Publishing Office, 20 June 2001

External links

Categories: